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Glomus tumors are small, benign mesenchymal neo-
plasms, the majority of which occur in the dermis or
subcutis of the extremities. The single most common site
is the subungual region of the ﬁngers, followed by palm,
wrist, forearm and foot. The tumor cells resemble mod-
iﬁed smooth muscle cells of normal glomus bodies.
Glomus tumors, however, have been reported in loca-
tions in which the glomus bodies are sparse or even ab-
sent, among them patella, nerve, eyelid, liver,
gastrointestinal tract, trachea, nose, bone and sella tur-
cica [3, 9]. Glomus tumors usually show a benign clinical
course. However, rare malignant cases have been re-
ported [5, 6, 7]. In a recent review on atypical and
malignant glomus tumors, Folpe et al. [3] have proposed
a classiﬁcation scheme, encompassing malignant glomus
tumors, symplastic glomus tumors, glomus tumors of
uncertain malignant potential and glomangiomatosis.
Glomus tumors in the sellar region are exceedingly
rare and to the best of our knowledge only one case has
been reported so far in this location [2]. Here we report
the case of an intra- and parasellar neoplasm ﬁrst
diagnosed as a benign glomus tumor. Recurrent tumor
growth was observed 8 and 10 years after the ﬁrst sur-
gical intervention and subsequent histology suggested
malignant progression of the glomus tumor.
In 1991, 9 months after a moderate cervical spine
trauma, the 47-year-old female patient noted intermit-
tent diplopia. Ophthalmological examination revealed a
right-sided cavernous sinus syndrome with palsy of the
occulomotor, trochlear and abducent nerves. Cranial
computer tomography and magnetic resonance imaging
(MRI) showed an intrasellar mass lesion that extended
into the right-sided supra- and parasellar regions
including the cavernous sinus. Microsurgical tumor
resection was performed with a right pterional craniot-
omy approach. The residual tumor was treated by
fractioned radiation therapy (27 fractions with a total
dose of 54 Gy). Apart from a persisting right-sided
trochlear nerve palsy the clinical history was uneventful
till May 1999, when the patient developed a right-sided
lid ptosis and an intermittent diplopia. On MRI scans,
the tumor was found to have recurred and expanded to
the right supra- and parasellar regions, now measuring
3 cm in diameter (Fig. 1A). Incomplete tumor resection
was performed via a transsphenoidal approach followed
by gamma knife radiosurgery with a total dose of 25 Gy.
In July 2001 the patient noted further visual impairment
and ophthalmological testing revealed loss of visual
acuity and visual ﬁeld defects in the right eye. Endocri-
nological examination demonstrated panhypopituita-
rism. Repeated MRI scans again showed tumor growth
in the right supra- and parasellar region measuring up to
3.5 cm in diameter. The patient underwent right-sided
pterional recraniotomy with incomplete tumor resection.
Due to progressive visual impairment a further trans-
sphenoidal tumor resection was undertaken in Novem-
ber 2001. Further radiation therapy was initially refused;
however, due to progressive tumor growth (Fig. 1B) a
targeted radiotherapy using 90Yttrium-DOTATOC, an
Yttrium-labeled somatostatin analogue, was conducted
early in 2003. The patient died in October 2003, 12 years
after initial manifestation of the tumor. No autopsy was
performed.
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Surgical specimens were all ﬁxed in 10% formalin,
routinely processed and embedded in paraﬃn. Five-
micrometer thin sections were cut and stained with
hematoxylin and eosin, periodic acid-Schiﬀ (PAS) and
silver reticulin stain. Immunohistochemistry was per-
formed, following standard protocols using a broad
panel of antibodies (see below). Small tumor fragments
were cut from paraﬃn-embedded tissue blocks and
processed for electron microscopy.
Histology of the initial tumor revealed a predomi-
nantly solid neoplasm composed of sheets of uniform
round and polygonal cells interrupted by small thin-
walled vessels (Fig. 1C). Vessels were not invaded by the
tumor. Tumor cells were of regular shape with a pun-
ched-out rounded nucleus, surrounded by clear, slightly
eosinophilic cytoplasm. The nuclei contained ﬁnely dis-
persed chromatin with an indistinct nucleolus. Silver
reticulin stain revealed a delicate ﬁber network sur-
rounding individual tumor cells or small cell groups.
Mitoses and necrosis were absent.
Fig. 1 A T1-weighted MRI scan of the ﬁrst recurrent tumor in
1999, showing predominantly right-sided parasellar contrast
enhancing mass with inﬁltration of the cavernous sinus and
compression of the temporal lobe. B T1-weighted MRI scan,
performed in early 2003, demonstrating the uniformly enhancing
intra-suprasellar mass with direct contact to the optic chiasm. C
Hematoxylin and eosin staining of the initial tumor. Uniform
round cells are arranged in sheets and interrupted by small vessels.
D, E The tumor after the second (D) and third (E) recurrence is
hypercellular, tumor cells and nuclei are more polymorphous, and
several mitoses can be seen (arrows). FMIB-1 labeling of the tumor
after third recurrence. G–I Immunostaining of the tumor after the
ﬁrst recurrence; G smooth muscle actin, H CD99, and I laminin
immunoreactivity. Bars A, B 1 cm; original magniﬁcation C ·200;
D, E, G–I ·400; F ·500
94
The histological appearance of the tumor specimens
obtained at the time of the second resection was quite
similar to that of the ﬁrst biopsy. However, there were
foci of higher cellularity, and tumor cells and the nuclei
appeared more polymorphous. One mitosis per 50
high-power ﬁelds (HPF) was noted, but there were no
atypical mitotic ﬁgures (Fig. 1D). Tumor necrosis was
absent. Histology from the third and forth biopsies was
found to be very similar to the second biopsy. In con-
trast to the previous tumor specimens, however, there
were more cellular and nuclear atypia. Up to 3 mitoses/
50 HPF were noted (Fig. 1E). Again, there was no tu-
mor necrosis.
Immunohistochemically, tumor cells stained strongly
for vimentin, smooth muscle actin, laminin and CD99
(Fig. 1G–I), and a few cells stained faintly for neuron-
speciﬁc enolase and epithelial membrane antigen. CD34
only stained the tumor vasculature. The MIB-1 prolif-
eration labeling index was below 1% in the initial tu-
mor, about 2% in the second tumor specimens and up
to 10% in the biopsies taken in 2001 (Fig. 1F). Tumor
cells were negative for chromogranin A, S-100 protein,
cytokeratin, placental alkaline phosphatase, synapto-
physin, glial ﬁbrillary acidic protein, desmin, CD117
and pituitary hormones.
Electron microscopy revealed medium-sized cells
with interdigitating microvilli on their surface. The
tumor cells possessed equally sized, sometimes slightly
grooved, nuclei with a nucleolus. The most prominent
cytoplasmic features consisted of sparse pinocytotic
vesicles, large mitochondria and focal aggregates of
microﬁlaments. Few individual cells were surrounded
by a layer of basal lamina. Cells were arranged ‘back
to back’ and were separated by bundles of long
spacing collagen.
Glomus tumor of the sellar region is rare. To our
knowledge, the case reported by Asa and coworkers
more than 20 years ago [2] is the only known case so
far. We now report histological, immunohistochemical
and electron microscopic ﬁndings of a second case of a
sellar glomus tumor. Similar to the case reported by
Asa et al. [2], recurrent tumor growth was also observed
in our patient.
Irrespective of their anatomical location glomus tu-
mors are usually benign, but rare malignant cases have
also been described [5, 6, 7]. In our case, benign glomus
tumor was diagnosed in a ﬁrst biopsy. However, in later
biopsies, hypercellularity, cellular and nuclear atypia,
increased mitotic activity and MIB-1 labeling indices
were noted, suggesting malignant transformation of the
glomus tumor.
Recently, Folpe et al. [3] proposed a classiﬁcation of
atypical and malignant glomus tumors. Malignant
glomus tumors are deﬁned as tumors with: (i) large size
(>2 cm) and deep location, (ii) atypical mitotic ﬁgures,
or (iii) marked atypia with mitotic activity (e.g., >5
mitoses/50 HPF). Symplastic glomus tumors lack cri-
teria for malignant glomus tumor and exhibit only
marked nuclear atypia. Glomus tumors of uncertain
malignant potential are deﬁned as tumors with: (i)
superﬁcial location with high mitotic activity, (ii) large
size only, or (iii) deep location only. Finally, glo-
mangiomatosis lacks criteria for malignant glomus tu-
mor or glomus tumor of uncertain potential, and shows
features of diﬀuse angiomatosis and excess glomus cells
[3]. In this series, 38% of malignant glomus tumors
metastasized, but metastatic disease was not seen in any
of the symplastic glomus tumors, glomus tumor of
uncertain malignant potential, or glomangiomatosis.
Our case does not fulﬁll the criteria proposed for
symplastic glomus tumors and glomangiomatosis, and
is, therefore, very unlikely to correspond to one of
these entities. There is still the question of whether our
case does represent a malignant glomus tumor or a
glomus tumor with uncertain malignant potential.
Atypical mitotic ﬁgures as well as marked atypia with
mitotic activity of more than 5 mitoses/50 HPF were
not features in our case. Since the tumor was deﬁnitely
larger than 2 cm and located deep in the sellar region,
it would nevertheless qualify for a malignant glomus
tumor. With regard to the sella turcica, however, the
criteria of ‘‘deep location’’ and ‘‘large size’’ need fur-
ther consideration. In their series of unusual glomus
tumors, Folpe et al. [3] deﬁned the tumor location as
either superﬁcial to the muscular fascia or deep to it.
In their study, ﬁve out of nine deeply located
peripheral soft tissue glomus tumors (all of which were
larger than 2 cm) metastasized. In a series of 32 gas-
trointestinal (GI) glomus tumors, there was only 1
case that metastasized, although all of these tumors by
deﬁnition were deeply located, and 19 of them were
larger than 2 cm [8]. In another series of gastric glo-
mus tumors, none of the 12 tumors metastasized,
including those which were larger than 2 cm [1]. Thus,
there seems to be a marked diﬀerence in the frequency
of malignant behavior between deep-seated glomus
tumors of the peripheral soft tissue and those located
in other ‘‘deep’’ regions. Taking this into account, a
deep location as well as a tumor size larger than 2 cm
may not per se be features of malignancy of a glomus
tumor in the sellar region. Clinical observations over
12 years for our patient did not reveal metastases, and
the same is true for the glomus tumor reported by Asa
et al. [2], although the follow-up in that case was only
6 years. However, both recurrent glomus tumors
showed a locally inﬁltrative growth pattern into the
supra- and parasellar region. Thus, according to an
earlier classiﬁcation proposed by Gould et al. [4], both
cases would represent examples of locally aggressive
and/or potentially malignant glomus tumors, or as
glomus tumors of uncertain malignant potential
according to the classiﬁcation by Folpe et al. [3]. Such
tumors may recur locally but usually do not metas-
tasize [4].
In conclusion, our case demonstrates that a glomus
tumor can occur within the sella turcica, and that it may
recur locally and invade the supra- and parasellar region
with an aggressive and inﬁltrative growth.
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